Details of the Drug

General Information of Drug (ID: DMSP0X8)

• Drug Name: IDAZOXAN HYDROCHLORIDE
• Synonyms: IDAZOXAN HYDROCHLORIDE; 79944-56-2; Idazoxan HCl; RX 781094; MLS000069708; SMR000058458; SR-01000000206; Opera_ID_847; Idazoxan (hydrochloride); AC1L4CEL; MLS001148081; SCHEMBL707367; CHEMBL543467; CTK8G0263; MolPort-003-941-824; MYUBYOVCLMEAOH-UHFFFAOYSA-N; (+/-)-Idazoxan Monohydrochloride; Pharmakon1600-01506073; HMS1570J14; Tox21_500652; NSC759867; MFCD00069293; BN0267; AKOS024458652; NSC-759867; RX 781094A; LP00652; CCG-214002; 1H-Imidazole, 2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-,monohydrochloride; 1H-Imidazole, 2-(2,3-d

Indication

Disease Entry	ICD 11	Status	REF
Neurological disorder	6B60	Phase 3	[1]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight; 240.68
  Logarithm of the Partition Coefficient; Not Available
  Rotatable Bond Count; 1
  Hydrogen Bond Donor Count; 2
  Hydrogen Bond Acceptor Count; 3
• Chemical Identifiers:
  Formula: C11H13ClN2O2
  IUPAC Name: 2-(2,3-dihydro-1,4-benzodioxin-3-yl)-4,5-dihydro-1H-imidazole;hydrochloride
  Canonical SMILES: C1CN=C(N1)C2COC3=CC=CC=C3O2.Cl
  InChI: InChI=1S/C11H12N2O2.ClH/c1-2-4-9-8(3-1)14-7-10(15-9)11-12-5-6-13-11;/h1-4,10H,5-7H2,(H,12,13);1H
  InChIKey: MYUBYOVCLMEAOH-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 154494
  CAS Number: 79944-56-2
  TTD ID: D01ZNH
• Drug ADMET Endpoint Profile (DAE)NEW: Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor alpha-2C (ADRA2C)	TT2NUT5	ADA2C_HUMAN	Modulator	[2]

Molecular Expression Atlas of This Drug

• The Studied Disease: Neurological disorder
• ICD Disease Classification: 6B60

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Adrenergic receptor alpha-2C (ADRA2C)	DTT	ADRA2C	1.76E-01	-0.06	-0.28

References

• [1] ClinicalTrials.gov (NCT00294944) The Effectiveness of Idazoxan in Treating TRD. U.S. National Institutes of Health.
• [2] Different sites of action for alpha 2-adrenoceptor antagonists in the modulation of noradrenaline release and contraction response in the vas deferens of the rat. J Pharm Pharmacol. 1992 Mar;44(3):231-4.